Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials

Am J Transplant. 2016 Nov;16(11):3077-3078. doi: 10.1111/ajt.13889. Epub 2016 Jul 1.
No abstract available

Keywords: clinical trial design; editorial/personal viewpoint; guidelines; immunosuppressant; immunosuppression/immune modulation.

Publication types

  • Editorial

MeSH terms

  • Abatacept / therapeutic use
  • Acute Disease
  • Endpoint Determination
  • Graft Rejection / drug therapy*
  • Humans
  • Immunosuppression Therapy*
  • Immunosuppressive Agents / therapeutic use*
  • Kidney
  • Kidney Transplantation*

Substances

  • Immunosuppressive Agents
  • Abatacept